louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06739889: Effects of ELAVl and CDOA vs Upper Thoracic Mobilization on Forward Head Posture in Upper Cross Syndrome
Official title: Effects of Elongation Longitudinaux Articular Vertebral and Columnar Decoaption Osteo-articulaire Versus Upper Thoracic Mobilization on Forward Head Posture in Upper Cross Syndrome
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cross Syndrome
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-12-18
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This randomized controlled study will examine the patient of forward head posture who suffering with upper cross syndrome. There will be comparison of two treatment methods 1st one is elongation longitudinaux articular vertebral and columnar decoaption osteo-articulaire also known as ELDOA and 2nd is upper thoracic mobilization .

Detailed description: This study includes 42 participants, both male and female, age between 20 to 45. ELDOA target the cervical and upper thoracic spine to improve range of motion, restore normal cervical and thoracic spine alignment and reduce muscle tension. Upper thoracic mobilization improve thoracic spine mobility and enhance cervical spine alignment.

Eligibility criteria: Inclusion Criteria:

* Adult between (20 to 45 year) with upper cross syndrome
* CVA angle less than 48-50 degrees.
* No history of spinal injury and fracture
* limited cervical range of motion

Exclusion Criteria:

* Severe spinal degeneration or deformity
* Injury or surgery
* Cervical radiculopathy
* Severe osteoporosis
* Malignancy of upper extremity of thorax
* Obesity

Primary outcomes:
measure: Tragus to wall test
timeFrame: 12 Months
measure: Craniovertebral angle assess
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Faisalābad
country: Pakistan
facility: Allied hospital, Masjid ismail Rd
state: Punjab
Study officials:
References:
Clinical trial NCT03201289: Microvolt T-wave Alternans in Cardiac Surgery Patients
Official title: Microvolt T-wave Alternans in Cardiac Surgery Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Complications
Electrocardiogram: Electrical Alternans
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-06-28
Enrollment: 224
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing cardiac surgery

Brief summary: The purpose of this study is to measure MTWA in the patients undergoing cardiac surgery and to investigate the relation between MTWA and adverse clinical outcomes.


Eligibility criteria: Inclusion Criteria:

* All patients underwent cardiac surgery including coronary artery bypass graft surgery with or without cardiopulmonary bypass, cardiac valve surgery, cardiac mass excision, thoracic aorta surgery, etc.

Exclusion Criteria:

* unavailability of the recording equipment

Primary outcomes:
measure: in hospital mortality
timeFrame: up to 3 months(during hospital stay)
Secondary outcomes:
measure: postoperative complication
timeFrame: up to 3 months(during hospital stay)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT03820089: Evaluation of TP US in Women With Prolapse
Official title: Evaluation of TP US Assesment of Women With Prolapse
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prolapse
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
Collaborators: name: Cairo University
First posted: 2019-01-29
Enrollment: 100
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women who complains from genital prolapse with previous normal deliveries

Brief summary: Many women suffers from uterine and vaginal prolapse Usually they suffer from these symotoms in menopause

Detailed description: The most common cause of pelvic organ prolapse is multiple pregnancy and multiparity

Eligibility criteria: Inclusion Criteria:

* Women with history of normal delivery Age between 25 to 75 years

Exclusion Criteria:

* women with cesarean deliveries

Primary outcomes:
measure: The number of women who will be properly diagnosed with prolapse by TP us
timeFrame: within 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Algazeerah and Kasralainy hospital
Study officials:
affiliation: Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
name: Mahmoud Alalfy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01451489: The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
Official title: A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: FSGS
Keywords: FSGS
FK506
CTX
Lead sponsor: Nanjing University School of Medicine
Sponsor class: OTHER
First posted: 2011-10-13
Enrollment: 70
Sex: ALL
Minimum age (years): 14
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective,multicentre study to compare the efficacy, safety, tolerability and relapse of FK506 versus CTX in the treatment of severe Focal Segmental Glomerulosclerosis (FSGS).

Detailed description: 1. Using the response rate and completely response time to compare the efficacy of FK506 versus CTX therapy for the severe FSGS patients.
2. To compare the safety and tolerability of FK506 versus CTX for the severe FSGS patients.

Eligibility criteria: Inclusion Criteria:

* patients with a diagnosis of FSGS.
* Patients with a proteinuria ≥ 3.5g/24h,and blood albumin \<30g/L,and Scr\< 2.3 mg/dl and eGFR\>30ml/min per 1.73m2.
* Patients who signed written informed consent form (patients less than 18 years old with their parents/legal representative's signatures), and have given their consent to follow all study procedures and follow-up.

Exclusion Criteria:

* Patients who have received treatment of FK506 in latest 2 month or the cumulative dose CTX≥6 g.
* Patients who are known to be allergic to a macrolide.
* Patients who have active hepatitis.
* Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit .
* Patients with blood leukocyte \< 3000/ul.
* Patients with kidney disease family history
* Patients with 2 type diabetes.
* Patients with obesity whose BMI\>28kg/m2.

Primary outcomes:
measure: the rates of the complete remission during the induction phase
timeFrame: 6 months
Secondary outcomes:
measure: the total remission rates
timeFrame: 18 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
state: Jiangsu
Study officials:
affiliation: Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
name: Zhihong Liu, MD
role: STUDY_DIRECTOR
References:
citation: Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3.
Clinical trial NCT06079489: The Effect of Telerehabilitation-Based Structured Exercise Program in Video Game-Addicted Adults
Official title: The Effect of Telerehabilitation-Based Structured Exercise Program in Video Game-Addicted Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Video Game Addiction
Lead sponsor: Biruni University
Sponsor class: OTHER
First posted: 2023-10-12
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The increasing use of computers and mobile devices due to advancing technology has brought with it some negative consequences such as video game addiction. Research has shown that playing video games for too long can lead to a number of acute and chronic serious musculoskeletal problems that can negatively affect health. The aim of the present study is to investigate the effect of telerehabilitation-based structured exercise program in video game-addicted adults and compare these effects with the effect of brochure-based exercise. Postural assessments, pain assessments, fine motor skill assessments, grip strength measurements, and reaction time assessments were performed. All assessments were repeated before and after the 8-week program for both groups. Participants in the EG were given a telerehabilitation-based structured exercise program for an average of 40 minutes three days a week for 8 weeks. Participants in the CG were given brochure-based exercises three days a week for 8 weeks.


Eligibility criteria: Inclusion Criteria:

* Being between 18-40 years old
* Having a score of ≥30 on the Game Addiction Inventory for Adults (GAIA)
* Volunteering to participate in the study
* Having high-speed internet, a camera, and a microphone

Exclusion Criteria:

* Having a neurological/orthopedic condition that would prevent exercise
* Having a cognitive impairment
* Having a vision or hearing loss

Primary outcomes:
measure: Pain Assessment
timeFrame: 1-2 minutes
measure: Fine Motor Skill Assessment
timeFrame: 4-5 minutes
measure: Posture Assessment
timeFrame: 5-10 minutes
measure: Hand Reaction Assessment
timeFrame: 10-15 minutes
measure: Handgrip Strength Assessment
timeFrame: 4-5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Biruni University
Study officials:
References:
Clinical trial NCT05478889: Minimally Invasive Pancreatoduodenectomy for Distal Cholangiocarcinoma
Official title: Surgical and Oncological Outcome After Minimally Invasive and Open Pancreatoduodenectomy for Distal Cholangiocarcinoma: an International Propensity Score Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Distal Cholangiocarcinoma
Keywords: Minimally invasive pancreatoduodenectomy
Whipple
Distal cholangiocarcinoma
Survival
Lead sponsor: Fondazione Poliambulanza Istituto Ospedaliero
Sponsor class: OTHER
First posted: 2022-07-28
Enrollment: 478
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All adult patients after elective upfront curative MIPD or OPD between January 1, 2010 and December 31, 2021 with a pathological confirmed dCCA

Brief summary: Outcomes for minimally invasive and open pancreatoduodenectomy for distal cholangiocarcinoma have not been compared. This is an international multicenter propensity score matched cohort study including patients after MIPD or OPD for dCCA. Primary outcomes included overall survival (OS) and disease-free interval (DFI).

Detailed description: This study is an international multicenter propensity score matched cohort study using the database of the International Study Group on non-pancreatic periAmpullary CAncer, the ISGACA consortium (www.isgaca.com), including all patients who underwent a pancreatoduodenectomy for non-pancreatic periampullary cancer. Data will be retrospectively collected. To minimize differences between groups, all the participating centers perform both OPD and MIPD and all centers meet the Miami guideline minimum volume of at least 20 MIPD per year. This study is approved by all the locals Ethical Committees (approval number from the promoting center, Comitato etico di Brescia, NP 5318 - 01.06.2022) and it will be performed according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE guideline and checklist), and the Declaration of Helsinki.

Eligibility criteria: Inclusion criteria:

* Adult patients
* Elective upfront curative MIPD or OPD between January 1, 2010 and December 31, 2021
* Pathological confirmed dCCA

Exclusion criteria:

* Neoadjuvant chemotherapy
* Palliative surgical procedures
* Intraoperative detection of unresectable disease (i.e., metastasis or locally advanced disease)
* Post-operative pathological diagnosis was other than dCCA (e.g., neuroendocrine tumor, polyposis adenoma)
* R2 positive resection margin
* Pregnancy
* Missing primary endpoints

Primary outcomes:
measure: Overall survival and disease-free interval
timeFrame: 60 months
Secondary outcomes:
measure: Major morbidity
timeFrame: 30 days or in-hospital
Other outcomes:
Locations:
city: Brescia
country: Italy
facility: Fondazione Poliambulanza Istituto Ospedaliero
Study officials:
affiliation: Fondazione Poliambulanza
name: Moh'd Abu Hilal, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06344689: Surgical Correction of Cicatricial Ectropion
Official title: The Surgical Correction of Cicatricial Ectropion: a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patients With Cicatricial Ectropion
Over 18-year-old
With Complete Clinical Record
Lead sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sponsor class: OTHER
First posted: 2024-04-03
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ectropion underwent surgical treatment in our center.

Brief summary: The main purpose of this study is to verify and compare the treatment effects of scarred ectropion surgery, perform statistical descriptions, compare patients undergoing tarsal strip and skin flap procedures with those undergoing simple skin flap treatment, and compare their pre- and post-operative Ectropion Grading Scale (EGS) and subjective and objective symptom changes.

Secondary Objective: To observe the incidence and resolution of complications after lower eyelid ectropion surgery. Compare postoperative effects among patients of different ages undergoing the same surgery.


Eligibility criteria: Inclusion Criteria:

* patients with Cicatricial Ectropion;
* over 18-year-old;
* with complete clinical record.

Exclusion Criteria:

* patients with severe complications

Primary outcomes:
measure: Ectropion Grading Scale
timeFrame: preoperative and one-year posttreatment
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai ninth people's hospital
Study officials:
References:
Clinical trial NCT05425589: Adjustable Strabismus Surgery
Official title: Adjustable Strabismus Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Strabismus
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 50
Sex: ALL
Minimum age (years): 5
Maximum age (years): 69
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Prospective, interventional study
Primary purpose: TREATMENT

Brief summary: Strabismus, whether congenital or acquired, is a common visual and cosmetic problem, especially for the young. Adjustable suture strabismus surgery is not in vogue in our country. This technique gives the surgeon a second attempt to provide a better outcome for the patients.


Eligibility criteria: Horizontal, vertical and complex strabismus cases (sensory, paralytic, nystagmus, monocular elevation deficit and dissociated vertical/horizontal deviation) were included, along with patients with a previous history of strabismus surgery.

Myasthenia gravis was excluded along with noncooperative children; less than 7 years of age. Those who did not return for a one year follow up also had to be excluded.

Primary outcomes:
measure: Post-operative alignment
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Fauji Foundation Hospital
state: Punjab
Study officials:
References:
Clinical trial NCT01545089: Use of a Fabric Mattress Cover for Patient Comfort
Official title: Use of a Fabric Mattress Cover for Patient Comfort
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patient Comfort
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2012-03-06
Enrollment: 174
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The main objective of this research project is to measure the impact on patient satisfaction of the use of a fabric mattress cover fabric on a bedsheet protecting a plastic mattress.


Eligibility criteria: Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* The patient has a planned hospitalization \> 4 days
* The patient is "movable" within 48 hours

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is pregnant
* The patient is breastfeeding

Primary outcomes:
measure: Visual analog scale for patient comfort
timeFrame: 2 days
measure: Visual analog scale for patient comfort
timeFrame: 4 days
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes Cedex 09
country: France
facility: CHU de Nîmes - Hôpital Universitaire Carémeau
state: Gard
Study officials:
affiliation: Centre Hospitalier Universitaire de Nîmes
name: Luc Duwig, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02132689: Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism
Official title: Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pulmonary Embolism
Keywords: Moderate Risk Acute Pulmonary Embolism
Lead sponsor: University Hospital Ostrava
Sponsor class: OTHER
Collaborators: name: Municipal Hospital Ostrava Fifejdy
name: Silesian Hospital Opava
First posted: 2014-05-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen as stated in the pulmonary embolism guidelines.

Detailed description: Standard treatment of moderate risk pulmonary embolism constitutes of sole anticoagulation therapy. In case of troponin positivity and/or echocardiographic findings as i.e. thrombi in RV thrombolytic therapy should be considered. The aim of this trial is to compare the two treatment modalities in their ability to reduce/predict 12 month end-point: pulmonary hypertension, right ventricular failure, exercise capacity.

Eligibility criteria: Inclusion Criteria:

* moderate risk pulmonary embolism as defined by the European Society of Cardiology /ESC/ guidelines
* signed informed consent

Exclusion Criteria:

* patient not willing to sigh informed consent
* absolute contraindication of thrombolysis
* inability to obtain meaningfull echocardiographic images¨
* pulmonary arterial hypertension
* known right ventricular failure

Primary outcomes:
measure: Clinical manifestations of right ventricular failure and pulmonary hypertension and cardiovascular-related death
timeFrame: 12 months
measure: Pulmonary hypertension
timeFrame: 12 months
measure: Cardiovascular-related deaths
timeFrame: 12 months
Secondary outcomes:
measure: Echocardiographic manifestations of right ventricular failure and pulmonary hypertension.
timeFrame: 12 months
Other outcomes:
Locations:
city: Opava
country: Czechia
facility: Silesian Hospital Opava
city: Ostrava-Poruba
country: Czechia
facility: University Hospital Ostrava
Study officials:
affiliation: Department of Cardiology, University Hospital Ostrava
name: Radovan Stancik, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03479489: Use of Human Dehydrated Amnion Chorion Allograft in Closed Hemorroidectomy
Official title: A Prospective Case Series for Closed Hemorrhoidectomy - Efficacy of External Hemorrhoid Repair Using a Dehydrated Human Amnion Chorion Membrane
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: External Hemorrhoid
External Hemorrhoid Thrombosed
Lead sponsor: MiMedx Group, Inc.
Sponsor class: INDUSTRY
First posted: 2018-03-27
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and effectiveness of human dehydrated amnion chorion allograft in closed hemorrhoidectomy as assessed by patient and wound assessments.


Eligibility criteria: Inclusion Criteria:

1. Confirmed diagnosis of acutely thrombosed hemorrhoid or an external hemorrhoid exceeding 72 hours in duration
2. Subject is undergoing closed hemorrhoidectomy as their definitive treatment for the Grade 2-4 hemorrhoid
3. Subject is age 18 or older
4. Subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study

Exclusion Criteria:

1. Subject has a known history of poor compliance with medical treatments
2. Subject has signs and symptoms of active cirrhosis
3. Subject has signs and symptoms of Crohn's disease complicated by perianal manifestations
4. Subject is currently taking immunosuppressive medications
5. Subject has had previous surgery in the target area within the past 6 months prior to treatment or plans to have surgery other than closed hemorrhoidectomy in the target area within 180 days of treatment
6. Subject is currently receiving radiation therapy or chemotherapy
7. Subject has used an investigational drug, device or biologic within 12 weeks prior to treatment
8. Subject is pregnant at enrollment or is planning to become pregnant within 180 days of treatment; subject intends to breastfeed during the course of the trial
9. Subject has any significant medical condition(s) that, in the opinion of the Investigator, would interfere with protocol evaluation and participation
10. Subject has an allergy or known sensitivity to aminoglycoside antibiotics such as gentamicin sulfate and/or streptomycin sulfate

Primary outcomes:
measure: Reported Patient Pain
timeFrame: 60 days
Secondary outcomes:
Other outcomes:
Locations:
city: Boulder
country: United States
facility: Boulder Valley Surgical Associates
state: Colorado
Study officials:
affiliation: MiMedx Group, Inc.
name: Donald Fetterolf, MD
role: STUDY_DIRECTOR
References: